At Saince, we build the technological foundation that empowers providers to focus entirely on their patients. By seamlessly integrating artificial intelligence, cloud-native infrastructure, and deep system interoperability, we are eliminating inefficiencies and bringing clinical information, radiology, and hospital management into the modern era. We are not just a service provider—we are a high-tech innovation engine for the healthcare industry.

USA: 5490 McGinnis Village Place, Suite 116, Alpharetta, GA 30005.
+1 888 472 4623 | sales@saince.com
INDIA: Corporate Address: #6-3-1090, Ground Floor, Block B, TSR Towers, Raj Bhavan Road, Somajiguda, Hyderabad, Telangana 500082.
Registered Address: #202, Shatabdi Residency, Ramnagargundu, Hyderabad, Telangana 500044.
+91 40 6728 5555 | sales@saince.in
Contact Us
Address 5490 McGinnis Village Place, Suite 116, Alpharetta, GA 30005.
Follow Us

Clinical documentation, imaging and intelligence solutions.

Blog Details

Blogs
Hybrid PET/MRI spares 20% of brain tumor patients from unnecessary follow-up treatment August 15, 2021

Hybrid PET/MRI spares 20% of brain tumor patients from unnecessary follow-up treatment

A molecular, hybrid imaging approach accurately detects malignant brain tumors while also preventing unnecessary invasive procedures, recently published research suggests.

Combined PET/MRI scanning with radiopharmaceuticals such as 18F-fluorethyl tyrosine (18F-FET) has proven to enhance diagnostic performance, but there’s less evidence such imaging impacts clinical decision-making. German researchers tested the approach in patients with brain tumors, reporting positive results.

Further studies considering these aspects might evaluate finally if 18F-FET PET/MR as a hybrid modality qualifies for evidence-based use in clinical routine.

Read the full article: https://www.healthimaging.com/topics/molecular/petmri-brain-tumor-patients-unnecessary-treatment